Search Results

Oral presentation unifies the respiratory and hepatic programs. The first-in-class, direct-acting, broad-spectrum, Thumb-1 polymerase inhibitor demonstrates single-agent activity against influenza, RSV, SARS-CoV-2, HCV, HBV, and HDV, including activity against oseltamivir-resistant influenza and oral in vivo proof-of-concept.

New 8,000-square-foot Laboratory and Office Facility in Salem, Massachusetts, will Provide Local Primary Human Mast Cell Production Capabilities to Address Increasing US Demand and Offer Faster Access to North American Researchers

AmesNet’s Task-Conditioned Learning architecture outperforms FDA, MIT, Tencent, and the University of Sydney models in both sensitivity and balanced accuracy on out-of-domain chemical data on a public dataset; AmesNet is built on top of ChemPrint, the core and proprietary deep-learning engine of the GALILEO platform that powers the company’s drug pipeline.